Sugi Predict

Sugi Predict / Compounds / SCHEMBL6550819

SCHEMBL6550819

SCHEMBL6550819

COc1ccc(C(=O)O)c(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ PTGDR2 Q9Y5Y4 1/20 0.53
▸ AKR1C3 P42330 3/20 0.52
▸ AKR1C2 P52895 3/20 0.52
▸ MAOB P27338 1/20 0.51
▸ CYP2C8 P10632 1/20 0.49
▸ BACE1 P56817 1/20 0.47
▸ KDM4E B2RXH2 4/20 0.47
▸ HPGD P15428 3/20 0.47
▸ CYP2C19 P33261 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ RXRA P19793 1/20 0.47
▸ RXRB P28702 1/20 0.47
▸ USP2 O75604 1/20 0.47
▸ PTPN11 Q06124 1/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ KCNK2 O95069 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29979130 1.00 SMN1; SMN2 (0.57) SMN1; SMN2PTGDR2AKR1C3AKR1C2MAOB
SCHEMBL6489098 0.89 SMN1; SMN2 (0.75) SMN1; SMN2PTGDR2AKR1C3AKR1C2MAOB
SCHEMBL6701426 0.87 KDM4E (0.58) SMN1; SMN2PTGDR2AKR1C3AKR1C2MAOB
SCHEMBL7591657 0.86 SMN1; SMN2 (0.75) SMN1; SMN2AKR1C3AKR1C2CYP2C8BACE1
SCHEMBL23354314 0.86 IGF2BP2 (0.49) AKR1C2CYP2C8BACE1KDM4EHPGD
SCHEMBL23354274 0.84 MAOB (0.47) SMN1; SMN2PTGDR2AKR1C3AKR1C2MAOB
SCHEMBL6778891 0.84 SMN1; SMN2 (0.62) SMN1; SMN2AKR1C3AKR1C2CYP2C8KDM4E
SCHEMBL23354157 0.83 KDM4E (0.59) PTGDR2CYP2C8BACE1KDM4EHPGD
SCHEMBL9683222 0.82 SMN1; SMN2 (0.64) SMN1; SMN2AKR1C3AKR1C2CYP2C8BACE1
SCHEMBL8566031 0.82 SMN1; SMN2 (0.64) SMN1; SMN2AKR1C3AKR1C2MAOBCYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383753-A1 PIPERAZINE-BENZAMIDE DERIVATIVES USEFUL AS APOB-100 AND/OR MTP INHIBITOR GLAXO GROUP LIMITED (GB) 2004-01-28 — — EP claimed
CN-1131222-C Benzamide derivatives and their use as inhibitors of APOB-100 secretion GLAXO GROUP LTD (GB) 2003-12-17 — — CN claimed
US-6552022-B1 Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels SMITHKLINE BEECHAM CORPORATION 2003-04-22 — — US claimed
WO-2002083658-A1 PIPERAZINE-BENZAMIDE DERIVATIVES USEFUL AS APOB-100 AND/OR MTP INHIBITOR GLAXO GROUP LIMITED (GB) 2002-10-24 — — WO claimed
CN-1334808-A Benzamide derivatives and their use as inhibitors of APOB-100 secretion GLAXO GROUP LTD (GB) 2002-02-06 — — CN claimed
EP-1135378-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS GLAXO GROUP LIMITED (GB) 2001-09-26 — — EP claimed
WO-2000032582-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS GLAXO GROUP LIMITED (GB) 2000-06-08 — — WO claimed
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 — — US disclosed
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 — — EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 — — US disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 — — US disclosed
EP-4058448-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 — — EP disclosed
WO-2021094436-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2021-05-20 — — WO disclosed
US-6552022-B1 Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels SMITHKLINE BEECHAM CORPORATION 2003-04-22 — — US disclosed
EP-1286670-A2 USE OF THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-03-05 — — EP disclosed
WO-2002083658-A1 PIPERAZINE-BENZAMIDE DERIVATIVES USEFUL AS APOB-100 AND/OR MTP INHIBITOR GLAXO GROUP LIMITED (GB) 2002-10-24 — — WO disclosed
CN-1334808-A Benzamide derivatives and their use as inhibitors of APOB-100 secretion GLAXO GROUP LTD (GB) 2002-02-06 — — CN disclosed
WO-2001097810-A2 USE OF THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2001-12-27 — — WO disclosed
EP-1135378-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS GLAXO GROUP LIMITED (GB) 2001-09-26 — — EP disclosed
WO-2000032582-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS GLAXO GROUP LIMITED (GB) 2000-06-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 SMN1; SMN2 3850/4885PTGDR2 1000/4885AKR1C3 1151/4885
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 SMN1; SMN2 3850/4885PTGDR2 1000/4885AKR1C3 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.